GEN Exclusives

More »

GEN News Highlights

More »
Aug 14, 2007

Regeneron Achieves $20M Landmark in Bayer Partnership

  • Regeneron Pharmaceuticals received a $20-million milestone fee from Bayer HealthCare. The payment was triggered by Regeneron dosing the first patient in its Phase III study of the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD).

    In October, 2006, Bayer coughed up $75 million to partner with Regeneron on the global development of the VEGF Trap-Eye. The company thus also gained ex-U.S. commercialization rights to the drug. Regeneron stands to earn an additional $20 million related to the Phase III trial and $205 million in total milestone payments.

    The VEGF Trap-Eye is a fully human, soluble VEGF receptor fusion protein that reportedly binds all forms of VEGF-A along with the related placental growth factor (PlGF). The VEGF Trap-Eye is a specific and highly potent blocker of these growth factors, according to the companies.

    This late-stage trial will be a noninferiority comparison of the VEGF Trap-Eye and Genentech’s Lucentis. The randomized, double-masked evaluation is expected to enroll approximately 1,200 patients.

    "Results of early-phase studies have shown that VEGF Trap-Eye has the potential to be an important addition to the treatment alternatives available for patients with wet AMD," reports Leonard S. Schleifer, M.D., Ph.D., president and CEO of Regeneron.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?